Contrasting Eterna Therapeutics (NASDAQ:ERNA) and Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX) and Eterna Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Earnings and Valuation

This table compares Anixa Biosciences and Eterna Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210,000.00	455.40	-$12.55 million	($0.39)	-7.62
Eterna Therapeutics	$70,000.00	27.74	-$21.67 million	($8.31)	-0.04

Anixa Biosciences has higher revenue and earnings than Eterna Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Anixa Biosciences and Eterna Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-58.55%	-53.29%
Eterna Therapeutics	-7,513.88%	N/A	-117.48%

Insider and Institutional Ownership

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are owned by institutional investors. 22.6% of Anixa Biosciences shares are owned by company insiders. Comparatively, 4.5% of Eterna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Anixa Biosciences and Eterna Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	0	0	2	1	3.33
Eterna Therapeutics	0	0	0	0	0.00

Anixa Biosciences presently has a consensus price target of $8.50, indicating a potential upside of 186.20%. Given Anixa Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Anixa Biosciences is more favorable than Eterna Therapeutics.

Risk & Volatility

Anixa Biosciences has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 4.29, meaning that its share price is 329% more volatile than the S&P 500.

Summary

Anixa Biosciences beats Eterna Therapeutics on 11 of the 15 factors compared between the two stocks.

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

About Eterna Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.